Remogliflozin is a novel SGLT2 inhibitor approved and available in India for the treatment of type 2 diabetes mellitus patients. This study was designed to determine the effect of Remogliflozin on diabetic nephropathy patients compared with placebo on the reduction of the albuminuria. We conducted a 24 week, double-blind, randomized, parallel-group study with 94 type 2 diabetics subjects with diabetic nephropathy (micro albuminuria range from 30 to 300) and HbA1c of 7.5 - 9.3%. Subjects were randomized to Remogliflozin (100 mg bid) and placebo with 1000 mg metformin OD. The primary end point was change in HbA1C from baseline, with secondary end points including change in fasting plasma glucose (FPG), body weight, and change in albuminuria. Safety and tolerability were also characterized. Result: As shown in Table in image.

Conclusion: Result of our study revealed that Remogliflozin significantly reduced albuminuria (p value <0.001) in type 2 diabetes mellitus patients with delay in progression of diabetic nephropathy as compared to placebo.


V.K. Gupta: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at